Healthcare and Life Science
Milner Therapeutics Symposium showcases innovation in translational science
Hosted at West Road Concert Hall in Cambridge, the Symposium brings together leading minds from academia and industry to showcase cutting-edge research and its translation into novel therapeutics. ...
Healx and SCI Ventures join forces to uncover cures for paralysis with AI-driven drug discovery
Healx, a pioneer in AI-powered drug discovery for rare and neglected conditions, has partnered with SCI Ventures - the world’s first specialist venture fund focused on curing paralysis- to accelerate the discovery and development of therapies for spinal cord injury (SCI) using artifici...
Optibrium partners with TalTech on EU-Funded PhD Programme to advance sustainable drug discovery
The research will focus on developing faster and more accurate methods for predicting drug metabolism ...
Founding fundraiser says Addenbrooke’s would not be what it is today without financial support of hospital charity
This month, Addenbrooke's Charitable Trust celebrates its 30th birthday. As the official charity for Addenbrooke’s, it funds high-tech equipment, specialist staff, extra comforts and vital research above and beyond what the NHS is able to provide. Here, one of the founding fundraisers, ...
New insights on genetic damage of some chemotherapies could guide future treatments with less harmful side effects
For the first time, scientists have systematically studied the genetic effects of chemotherapy on healthy tissues. Researchers from the Wellcome Sanger Institute, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust (CUH) and their collaborators analysed bloo...
Shift Bioscience proposes improved ranking system for virtual cell models to accelerate gene target discovery
Study identifies new metrics to enhance scRNA-seq based virtual cell modellingFoundational paper to drive development of improved virtual cell models for rejuvenation target discoveryCambridge, UK, 1 July 2025: Shift Bioscience (Shift), a biotechnology company uncovering the biolog...
4basebio introduces new branding to reflect next phase of growth enabling development of advanced genetic therapies
4basebio PLC, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today (01 July 2025) announced refreshed branding and the launch of its new website, reflecting the company’s continued growth and success in this rapidly advancing field. ...
Navigating policy shifts and funding challenges
Co-authored Cassie McGrathThe healthcare industry is facing a period of unprecedented uncertainty. As the political landscape shifts in the US, hospitals and healthcare providers are grappling with potential funding cuts that could disrupt patient care and long term innovation. In a rec...
Guardtech Group set for Suffolk Business Awards showcase to kick off trio of events
The Haverhill-based contamination control specialists are up for the Large Business of the Year prize next month before setting their sights on two more awards later in the year. ...
Cambridge Cognition investment, Monument Therapeutics, achieves positive Phase I results for novel schizophrenia treatment
Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is pleased to report that Monument Therapeutics, in which the Group has a 20% holding, has achieved positive topline results from its...